Even amid the thick of earnings season, biotech stocks sway to the din produced by catalytic events, which include PDUFA action
dates.
Here's a rundown on the PDUFA dates scheduled for the month of May.
1. Will Second Time Be Charm For Portola?
-
Company: Portola Pharmaceuticals Inc (NASDAQ: PTLA)
- Type of Application: BLA
- Candidate: Andexanet alfa
- Indication: A factor Xa inhibitor (anti-coagulants) reversal agent
- Date: May 4
The FDA had issued a CRL for the pipeline
candidate in August 2016. Following a resubmission, the agency set a revised PDUFA date of Feb. 2, 2018, which was extended by
three months to give enough time to parse additional data from the ongoing ANNEXA-4 study.
2. Will FDA Go Against Panel Vote On Lipocine's Testosterone Deficiency Drug?
-
Company: Lipocine Inc (NASDAQ: LPCN)
- Type of Application: NDA
- Candidate: Tlando (LPCN 1021)
- Indication: conditions associated with a deficiency of endogenous testosterone, aka hypogonadism
- Date: May 8
The regulatory path for this testosterone replacement therapy has been rocky, as the FDA issued a CRL in June 2016, requesting
additional information related to the dosing algorithm for the proposed label. Following a resubmission, the FDA accepted the
application as a complete response and set a new PDUFA goal date of Feb. 8, which was subsequently extended by three months.
The company suffered another setback as an FDA panel, which met in January, voted 13-6 against the benefit/risk profile of
Tlando.
3. Valeant Seeks FDA Clearance For Bowel Cleaning Drug
-
Company: Valeant Pharmaceuticals Intl Inc (NYSE: VRX)
- Type of Application: NDA
- Candidate: Plenvu,code named NER1006
- Indication: bowel cleansing
- Date: May 13
The FDA had accepted the NDA filed by Salix Pharma, which has since then been acquired by Valeant, in July 2017. In February,
Salix said the FDA has extended the review period by three
months.
Related Link: The
Week Ahead In Biotech: PDUFA Dates, Clinical Trials, Merck And Pfizer Earnings On Tap
4. Can Amgen's Migraine Drug Pass The Muster?
-
Company: Novartis AG (ADR) (NYSE: NVS) and Amgen, Inc. (NASDAQ: AMGN)
- Type of Application: BLA
- Candidate: Aimovig (Erenumab)
- Indication: Migraine
- Date: May 17
The pipeline candidate, touted to be the first-and-only monoclonal antibody targeting the calcitonin gene-related peptide
receptor, was accepted for review by the FDA in July 2017.
5. Dova's Drug to Treat Low Platelet Count
-
Company: Dova Pharmaceuticals Inc (NASDAQ: DOVA)
- Type of Application: NDA
- Candidate: Avatrombopag
- Indication: Thrombocytopenia in chronic liver disease patients
- Date: May 21
The FDA had accepted the NDA for avatrombopag in November 2017, while also giving it priority review status. The submission was
based on two Phase 3 trials ADAPT 1 and ADAPT 2, in which the drug candidate met all primary and secondary end points.
Thrombocytopenia is a condition where the platelet count drops to low levels, causing internal bleeding.
6. Johnson & Johnson Unit Seeks FDA Nod For Partner Genmab's Cancer Drug
-
Company: Johnson & Johnson (NYSE: JNJ)'s Janssen unit & GENMAB A/S/S ADR (OTC: GMXAY)
- Type of Application: sBLA
- Candidate: Darzalex (Daratumumab)
- Indication: Frontline multiple myeloma
- Date: May 21
The FDA granted priority review status to the sBLA for darzalex in combination with bortezomib, melphalan and prednisone for
treating patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant.
7. Biomarin Knocks FDA Altar For Pegvaliase
-
Company: BioMarin Pharmaceutical Inc. (NASDAQ: BMRN)
- Type of Application: BLA
- Candidate: Pegvaliase
- Indication: Phenylketonuria
- Date: May 25
The NDA was accepted with a priority review status in August 2017, while the agency also sought additional information on
chemistry, manufacturing and controls. The information, being a major amendment to the BLA, led to a three-month extension to the
PDUFA action date.
Phenylketonuria is a disorder involving deficiency of phenylalanine hydroxylase, an enzyme needed for metabolism of an essential
amino acid present in most protein-containing food. An accumulation of this amino acid in the blood is toxic to the brain.
8. Recro Gears For Gain For its Pain Medication
-
Company: Recro Pharma Inc (NASDAQ: REPH)
- Type of Application: NDA
- Candidate: intravenous meloxicam
- Indication: Acute pain following bunionectomy surgery
- Date: May 26
9. Amgen Seeks Approval for Expanded Use of Osteoporosis Drug
- Company: Amgen
- Type of Application: sBLA
- Candidate: Prolia (denosumab)
- Indication: Glucocorticoid-induced osteoporosis
- Date: May 28
Glucocorticoid-induced osteoporosis is the most common form of secondary osteoporosis arising from the intake of Glucocorticoid
medications used to treat inflammation. Prolia has already been approved for treating postmenopausal women with osteoporosis at
high risk for fracture.
10. TherapeuticsMD Sets Out to Allay Safety Concerns for Yuvvexy
-
Company: TherapeuticsMD Inc (NASDAQ: TXMD)
- Type of Application:
- Candidate: Yuvvexy, code-named TX-004HR
- Indication: moderate-to-severe vaginal pain
- Date: May 29
The FDA issued a CRL for the company's original NDA filing in May 2017, seeking additional endometrial safety information.
Following a resubmission, the FDA accepted it as a complete class 2 response in December 2017.
© 2018 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.